Varicella vaccination with Pulmicort

Study identifier:SD-004-0758

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Rates of Seroconversion following Varicella Vaccination of Asthmatic children between the ages of One and Eight Years treated with Pulmicort Respules® versus Non-Steroidal Conventional Asthma Therapy

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

Study drug

budesonide, varicella zoster virus

Sex

All

Actual Enrollment

250

Study type

Interventional

Age

10 Months - 8 Years

Date

Study Start Date: 01 Oct 2001

Primary Completion Date: 01 Oct 2003

Study Completion Date: 01 Oct 2003

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Pulmicort	-
Active Comparator: 2 Varivax	-

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1100&filename=CSR-SD-004-0758.pdf
Download
CSR-SD-004-0758.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Bertill Andersson

AstraZeneca employee